Comparison of Two Naloxone Regimens in Opioid-dependent Methadoneoverdosed Patients: A Clinical Trial Study.
Current clinical pharmacology · 2017-01-01 · Randomised trial
Abstract
BACKGROUND: Methadone toxicity is one of the major causes of death in opioiddependent individuals. OBJECTIVE: We aimed to compare two different protocols of naloxone administration in terms of reversal of overdose signs and symptoms and frequency of complications in opioid-dependent methadone-intoxicated patients. METHOD: One-hundred opioid-dependent patients with signs/symptoms of methadone overdose were included. The patients were consecutively assigned into Tintinalli (group 1) or Goldfrank regimen protocol (group 2) of naloxone administration. Group 1 received naloxone with the dose 0.1 mg given every two to three minutes while group 2 received naloxone with the initial dose of 0.04 mg increasing to 0.4, 2, and 10 mg every two to three minutes to reverse respiratory depression. They were then compared regarding reversal of toxicity and risk of development of complications. RESULTS: The time to reversal of the overdose signs/symptoms was significantly less in Goldfrank regimen protocol (P<0.001). Frequency of withdrawal syndrome and recurrence of respiratory depression were not significantly different between the two groups. Aspiration pneumonia and intubation were more frequent in group 2, as well. CONCLUSION: It seems that gradual titration of naloxone by Tintinalli protocol can reduce major complications compared to the Goldfrank regimen. However, this protocol was not perfect in opioid-dependent methadone-overdosed patients, either, since it could induce complications, as well. We may need new protocols in overdosed opioid-dependent patients.
Abstract © the authors or publisher, via PubMed. Reuse and removal
Tags
Poisoning & substance use · Antidotes · Methadone & buprenorphine · Naloxone
Related articles
- Buprenorphine to reverse respiratory depression from methadone overdose in opioid-dependent patients: a prospective randomized trial. (Crit Care, 2020)
- Starting a Prehospital Medication for Opioid Use Disorder Program. (Prehosp Disaster Med, 2024)
- Prehospital Buprenorphine in Treating Symptoms of Opioid Withdrawal - A Descriptive Review of the First 131 Cases in San Francisco, CA. (Prehosp Emerg Care, 2025)
- Prehospital Buprenorphine Treatment for Opioid Use Disorder by Paramedics: First Year Results of the EMS Buprenorphine Use Pilot. (Prehosp Emerg Care, 2023)
- Characteristics of Patients Experiencing Opioid Overdose and Eligibility for Prehospital Treatment with Buprenorphine. (Prehosp Emerg Care, 2025)
- Emergency Department-Administered Extended-Release Buprenorphine After Fentanyl Overdose Reversed by Emergency Medical Services With Naloxone. (J Emerg Med, 2026)